Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia

To investigate the potential use of accelerator mass spectrometry (AMS) in the study of the clinical pharmacology of imatinib. Six patients who were receiving imatinib (400 mg/d) as part of their ongoing treatment for chronic myeloid leukemia (CML) received a dose containing a trace quantity (13.6 k...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 13; no. 14; p. 4164
Main Authors:	Boddy, Alan V, Sludden, Julieann, Griffin, Melanie J, Garner, Colin, Kendrick, John, Mistry, Pritesh, Dutreix, Catherine, Newell, David R, O'Brien, Stephen G
Format:	Journal Article
Language:	English
Published:	United States 15.07.2007
Subjects:	Adult Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Female Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Mass Spectrometry Middle Aged Particle Accelerators Piperazines - pharmacokinetics Piperazines - therapeutic use Polymerase Chain Reaction Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use
ISSN:	1078-0432
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!